Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

doi:10.1200/JCO.2008.16.1612

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2008

Schneider Bryan P, Wang Molin, Radovich Milan, Sledge George W, Badve Sunil, Thor Ann, Flockhart David A, Hancock Bradley, Davidson Nancy, Gralow Julie, Dickler Maura, Perez Edith A, Cobleigh Melody, Shenkier Tamara, Edgerton Susan, Miller Kathy D

Abstract excerpt

PURPOSE: No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genotype

Share to Haplotypes

Share to Hypertension

Share to Polymorphism, Single Nucleotide

Share to Survival Rate

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 18824714
DOI: 10.1200/JCO.2008.16.1612
PMCID: PMC2653128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.PMID 18824714Read ↗

The role of vascular endothelial growth factor genetic variability in cancer.Semantic proximity Read ↗

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.Semantic proximity Read ↗

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.Semantic proximity Read ↗

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Semantic proximity Read ↗

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.Semantic proximity Read ↗

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.Semantic proximity Read ↗

Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.Semantic proximity Read ↗

Genetic markers of bevacizumab-induced hypertension.Semantic proximity Read ↗

Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.Semantic proximity Read ↗

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.Semantic proximity Read ↗

Vascular endothelial growth factor polymorphisms affect gene expression and tumor aggressiveness in patients with breast cancer.Semantic proximity Read ↗

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.